Premium
Controlled Trials Comparing Reteplase with Alteplase and Streptokinase in Patients with Acute Myocardial Infarction
Author(s) -
Amsterdam Ezra A.
Publication year - 1996
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1996.tb03666.x
Subject(s) - reteplase , streptokinase , medicine , myocardial infarction , tissue plasminogen activator , tenecteplase , clinical trial , intensive care medicine , fibrinolytic agent , thrombolysis , fibrinolytic therapy , plasminogen activator
Although the ability of a thrombolytic agent to lyse a clot has been recognized for over 50 years, it was not until recently that this form of therapy was used to treat acute myocardial infarction. The need for rapid diagnosis and timely treatment to provide optimum outcomes and prognosis is now well established. Numerous clinical trials continue to examine alternative therapeutic regimens as well as the efficacy and safety of new agents to improve short‐ and long‐term outcomes further. Reteplase is a new recombinant tissue‐type plasminogen activator with potential advantages over currently available agents.